Verteporfin suppresses osteosarcoma progression by targeting the Hippo signaling pathway

Yang,Xianliang; Xu,Youjia; Jiang,Chao; Ma,Ziping; Jin,Linguang

doi:10.3892/ol.2021.12985

Verteporfin suppresses osteosarcoma progression by targeting the Hippo signaling pathway

Authors:
- Xianliang Yang
- Youjia Xu
- Chao Jiang
- Ziping Ma
- Linguang Jin
View Affiliations

Affiliations: Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China, Department of Orthopedics, The First People's Hospital of Wenling Hospital, Wenling, Zhejiang 317500, P.R. China
Published online on: August 10, 2021 https://doi.org/10.3892/ol.2021.12985
Article Number: 724
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Verteporfin (VP) is a specific inhibitor of yes‑associated protein 1 (YAP1) that suppresses tumor progression by inhibiting YAP1 expression. The present study aimed to determine the inhibitory effect of VP on osteosarcoma and the underlying mechanism of its anticancer effects. Cell viability, cell cycle and apoptosis and cell migration and invasion were analyzed using the MTT assay, flow cytometry, wound healing assay and Transwell assay, respectively. Expressions of YAP1 and TEA domain transcription factor 1 (TEAD1) were measured using reverse transcription‑quantitative PCR and western blotting, while their interaction was identified by the co‑immunoprecipitation assay. In vivo mouse xenograft experiments were performed to evaluate the effect of VP on osteosarcoma growth. The results demonstrated that YAP1 and TEAD1 were highly expressed in osteosarcoma cells and tissues, whereas VP significantly downregulated the expression levels of YAP1 and TEAD1 in the osteosarcoma cell line Saos‑2 compared with those in untreated control cells. In addition, compared with those in the control group, VP suppressed the viability, migration and invasion, induced cell cycle arrest in the G1 phase and promoted apoptosis in Saos‑2 cells. In addition, VP inhibited mouse xenograft tumor growth in vivo compared with that observed in the control group. Notably, VP downregulated the levels of CYR61 expression in Saos‑2 cells, whereas CYR61 overexpression mitigated the inhibitory effects of VP on osteosarcoma cells, as indicated by the increased viability and reduced apoptotic rates in Saos‑2 cells overexpressing CYR61 compared with those in the control group. In summary, VP suppressed osteosarcoma by downregulating the expression of YAP1 and TEAD1. Additionally, CYR61 may mediate the effects of VP on osteosarcoma progression.

View Figures

View References

1	Shi K, Wang SL, Shen B, Yu FQ, Weng DF and Lin JH: Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma. World J Surg Oncol. 17:232019. View Article : Google Scholar : PubMed/NCBI
2	Lokau J, Schoeder V and Garbers C: The role of interleukin-11 in osteosarcoma. Pathologe. 41:163–167. 2020.(In German). View Article : Google Scholar : PubMed/NCBI
3	Mason NJ: Comparative immunology and immunotherapy of canine osteosarcoma. Adv Exp Med Biol. 1258:199–221. 2020. View Article : Google Scholar : PubMed/NCBI
4	Lin CH, Guo Y, Ghaffar S, McQueen P, Pourmorady J, Christ A, Rooney K, Ji T, Eskander R, Zi X and Hoang BH: Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma. 2013:1475412013. View Article : Google Scholar : PubMed/NCBI
5	Czarnecka AM, Synoradzki K, Firlej W, Bartnik E, Sobczuk P, Fiedorowicz M, Grieb P and Rutkowski P: Molecular biology of osteosarcoma. Cancers (Basel). 12:21302020. View Article : Google Scholar : PubMed/NCBI
6	Kansara M, Teng MW, Smyth MJ and Thomas DM: Translational biology of osteosarcoma. Nat Rev Cancer. 14:722–735. 2014. View Article : Google Scholar : PubMed/NCBI
7	Han G, Wang Y and Bi W: C-Myc overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway. Oncol Res. 20:149–156. 2012. View Article : Google Scholar : PubMed/NCBI
8	Maire G, Martin JW, Yoshimoto M, Chilton-MacNeill S, Zielenska M and Squire JA: Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet. 204:138–146. 2011. View Article : Google Scholar : PubMed/NCBI
9	Sun ZY, Jian YK, Zhu HY and Li B: lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway. Pathol Res Pract. 215:555–563. 2019. View Article : Google Scholar : PubMed/NCBI
10	Sun Y, Jiang T, Jia Y, Zou J, Wang X and Gu W: LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway. Cell Cycle. 18:2509–2523. 2019. View Article : Google Scholar : PubMed/NCBI
11	Johnson R and Halder G: The two faces of Hippo: Targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 13:63–79. 2014. View Article : Google Scholar : PubMed/NCBI
12	Chai J, Xu S and Guo F: TEAD1 mediates the oncogenic activities of Hippo-YAP1 signaling in osteosarcoma. Biochem Biophys Res Commun. 488:297–302. 2017. View Article : Google Scholar : PubMed/NCBI
13	Chan LH, Wang W, Yeung W, Deng Y, Yuan P and Mak KK: Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. Oncogene. 33:4857–4866. 2014. View Article : Google Scholar : PubMed/NCBI
14	Kyriazoglou A, Liontos M, Zakopoulou R, Kaparelou M, Tsiara A, Papatheodoridi AM, Georgakopoulou R and Zagouri F: The role of the hippo pathway in breast cancer carcinogenesis, prognosis, and treatment: A systematic review. Breast Care (Basel). 16:6–15. 2021. View Article : Google Scholar : PubMed/NCBI
15	Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B, Rosato A, Bicciato S, Cordenonsi M and Piccolo S: Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol. 17:1218–1227. 2015. View Article : Google Scholar : PubMed/NCBI
16	Zhang H, Ramakrishnan SK, Triner D, Centofanti B, Maitra D, Győrffy B, Sebolt-Leopold JS, Dame MK, Varani J, Brenner DE, et al: Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. Sci Signal. 8:ra982015. View Article : Google Scholar : PubMed/NCBI
17	Chen WS, Cao Z, Krishnan C and Panjwani N: Verteporfin without light stimulation inhibits YAP activation in trabecular meshwork cells: Implications for glaucoma treatment. Biochem Biophys Res Commun. 466:221–225. 2015. View Article : Google Scholar : PubMed/NCBI
18	Andrade D, Mehta M, Griffith J, Panneerselvam J, Srivastava A, Kim TD, Janknecht R, Herman T, Ramesh R and Munshi A: YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways. Oncotarget. 8:98495–98508. 2017. View Article : Google Scholar : PubMed/NCBI
19	Pan W, Wang Q, Zhang Y, Zhang N, Qin J, Li W, Wang J, Wu F, Cao L and Xu G: Verteporfin can reverse the paclitaxel resistance induced by YAP over-expression in HCT-8/T cells without photoactivation through inhibiting YAP expression. Cell Physiol Biochem. 39:481–490. 2016. View Article : Google Scholar : PubMed/NCBI
20	Lu Q, Lv G, Kim A, Ha JM and Kim S: Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma. Oncol Lett. 5:201–207. 2013. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Wang DY, Wu YN, Huang JQ, Wang W, Xu M, Jia JP, Han G, Mao BB and Bi WZ: Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance. Chin J Cancer. 35:472016. View Article : Google Scholar : PubMed/NCBI
23	Zanconato F, Cordenonsi M and Piccolo S: YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016. View Article : Google Scholar : PubMed/NCBI
24	Sun D, Wang Y, Wang H and Xin Y: The novel long non-coding RNA LATS2-AS1-001 inhibits gastric cancer progression by regulating the LATS2/YAP1 signaling pathway via binding to EZH2. Cancer Cell Int. 20:2042020. View Article : Google Scholar : PubMed/NCBI
25	Liu YP, Pan LL and Kong CC: Stathmin 1 promotes the progression of liver cancer through interacting with YAP1. Eur Rev Med Pharmacol Sci. 24:7335–7344. 2020.PubMed/NCBI
26	Ajani JA, Xu Y, Huo L, Wang R, Li Y, Wang Y, Pizzi MP, Scott A, Harada K, Ma L, et al: YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut. 70:55–66. 2021. View Article : Google Scholar : PubMed/NCBI
27	Zhou Y, Huang T, Cheng AS, Yu J, Kang W and To KF: The TEAD family and its oncogenic role in promoting tumorigenesis. Int J Mol Sci. 17:1382016. View Article : Google Scholar : PubMed/NCBI
28	Zhou Y, Huang T, Zhang J, Wong CC, Zhang B, Dong Y, Wu F, Tong JHM, Wu WKK, Cheng ASL, et al: TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis. Oncogene. 36:6518–6530. 2017. View Article : Google Scholar : PubMed/NCBI
29	Zheng Y and Pan D: The hippo signaling pathway in development and disease. Dev Cell. 50:264–282. 2019. View Article : Google Scholar : PubMed/NCBI
30	Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, et al: Comprehensive molecular characterization of the hippo signaling pathway in cancer. Cell Rep. 25:1304–1317.e5. 2018. View Article : Google Scholar : PubMed/NCBI
31	Yimlamai D, Fowl BH and Camargo FD: Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol. 63:1491–1501. 2015. View Article : Google Scholar : PubMed/NCBI
32	Plouffe SW, Hong AW and Guan KL: Disease implications of the Hippo/YAP pathway. Trends Mol Med. 21:212–222. 2015. View Article : Google Scholar : PubMed/NCBI
33	Hong L, Cai Y, Jiang M, Zhou D and Chen L: The Hippo signaling pathway in liver regeneration and tumorigenesis. Acta Biochim Biophys Sin (Shanghai). 47:46–52. 2015. View Article : Google Scholar : PubMed/NCBI
34	Liu K, Du S, Gao P and Zheng J: Verteporfin suppresses the proliferation, epithelial-mesenchymal transition and stemness of head and neck squamous carcinoma cells via inhibiting YAP1. J Cancer. 10:4196–4207. 2019. View Article : Google Scholar : PubMed/NCBI
35	Park MH, Kim AK, Manandhar S, Oh SY, Jang GH, Kang L, Lee DW, Hyeon DY, Lee SH, Lee HE, et al: CCN1 interlinks integrin and hippo pathway to autoregulate tip cell activity. Elife. 8:e460122019. View Article : Google Scholar : PubMed/NCBI
36	Zhou X, Rao Y, Sun Q, Liu Y, Chen J and Bu W: Long noncoding RNA CPS1-IT1 suppresses melanoma cell metastasis through inhibiting Cyr61 via competitively binding to BRG1. J Cell Physiol. 234:22017–22027. 2019. View Article : Google Scholar : PubMed/NCBI
37	Xie L, Song X, Lin H, Chen Z, Li Q, Guo T, Xu T, Su T, Xu M, Chang X, et al: Aberrant activation of CYR61 enhancers in colorectal cancer development. J Exp Clin Cancer Res. 38:2132019. View Article : Google Scholar : PubMed/NCBI
38	Fromigue O, Hamidouche Z, Vaudin P, Lecanda F, Patino A, Barbry P, Mari B and Marie PJ: CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis. J Bone Miner Res. 26:1533–1542. 2011. View Article : Google Scholar : PubMed/NCBI